Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
Basal Cell Nevus Syndrome
DRUG: Patidegib Topical Gel, 2%
Incidence of Treatment-emergent Adverse Events (TEAEs), IMP=Investigational medicinal product; Unique adverse event = adverse event of a certain preferred term, counted only once within each subject.

Related adverse event = adverse event with relationship as Definitely, Probably or Possibly., 12 months
Change in Number of Facial BCCs Removed by Surgery, 12 months|Change in Number of New Lesions Suspicious for BCC, 12 months|Change in Advanced Basal Cell Carcinoma Index (aBCCdex) Lesion Score, 12 months|Change in Dermatology Life Quality Index (DLQI), 12 months|Change in EuroQol Group 5-level EQ 5D (EQ 5D 5L), 12 months
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.